MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

40.24 -0.15 (-0.37%)
Delayed Quote Updated: 10:36 AM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
35 36 Next >
News headline image
Oil Output Cut May Tip Global Economy Into Recession, Elon Musk's Starship's First Space Tourist, Alphabet Approves Distribution Of Trump's Truth Social App: Top Stories Thursday, Oct. 13 ↗
Reuters 
Via Benzinga
News headline image
FDA Signals Shortage For Teva Pharma's ADHD Drug Due To Manufacturing Delay ↗
The FDA said that there was a shortage of Adderall after intermittent manufacturing delays at Teva Pharmaceutical Industries Ltd (NYSE: TEVA). 
Via Benzinga
News headline image
Teva Under Suspicion On Practices To Stave Off Copaxone Competition ↗
The European Commission, in an interim view, says Teva Pharmaceutical Industries Ltd (NYSE: TEVA) breached European Union (EU) antitrust rules over practices delaying competition to the multiple... 
Via Benzinga
News headline image
Teva Reaches Agreement With Arkansas to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva To Start Nationwide Settlement Of Opioid Lawsuits From Next Year: Report ↗
 
Via Benzinga
News headline image
Teva's Migraine Treatment Effective In Patients With Co-Morbid Depression ↗
 
Via Benzinga
News headline image
Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
European Drug Makers Say Higher Energy Costs Eating Margins: Report ↗
Europe's drug makers have warned about stopping manufacturing some cheap generic medicines amid surging electricity costs. 
Via Benzinga
News headline image
Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD Chorea
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Biden Announces $1.5B To Combat US Overdose Epidemic, Support Recovery ↗
 
Via Benzinga
News headline image
Top Financial Media Stories Monday, September 19: Apple iPhone 14's Glitch With Some Third Party Apps, Tesla Wants To Double Sales In Germany, Ford Working On Smartphone Based Crash Detection Tech And More.. ↗
Reuters Volkswagen Eyes Juicy Valuations For Porsche IPO 
Via Benzinga
News headline image
Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucentis®**, for age-related macular degeneration (AMD) the most common cause of blindness in developed countries
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Is Sanofi A Buy, Despite Recent Stumbles?
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions. 
Via MarketBeat
Topics Intellectual Property
News headline image
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday ↗
  Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Volume Surges Spark Turnarounds for These 3 Stocks
There are countless historical chart examples of high volume moves that mark the beginning of sustained rallies or slumps. Let’s tune into a few examples. 
Via MarketBeat
Topics Lawsuit
News headline image
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus... 
Via Benzinga
News headline image
Why This Teva Pharmaceuticals Analyst Is Turning Bullish 'The Most Room To Re-Rate' ↗
Following Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) opioid settlement, the Tel Aviv-Yafo, Israel-based company seems to be making “material progress” in clearing its litigation overhangs. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Synaptics To $205? Plus Stifel Cuts Twilio's PT From $200 To This Level ↗
Stifel cut the price target for Twilio Inc. (NYSE: TWLO) from $200 to $90. Twilio shares fell 9.6% to $88.75 in pre-market trading. 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Teva Pharmaceutical Indus ↗
Analysts have provided the following ratings for Teva Pharmaceutical Indus (NYSE:TEVA) within the last quarter: 
Via Benzinga
News headline image
Cramer Says This Stock Is Losing Money As 'Too Many Companies Doing The Same Thing' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended selling Marqeta Inc (NASDAQ: MQ) adding that "too many companies doing the same thing as they are, and they’re losing money." 
Via Benzinga
News headline image
Bausch Health (BHC) Stock Plunges 50% on Patent News ↗
With Bausch Health losing a critical patent battle enabling its key drug to suffer generic competition, BHC stock veritably crumbled. 
Via InvestorPlace
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story